Skip to content
Sign in

MTNB · AMEX

Matinas BioPharma Holdings (MTNB) Stock Price & Fundamentals

$901.95−0.03%−$0.24End-of-day price as of Oct 9, 2026

Matinas BioPharma Holdings (MTNB) closed at $901.95 on Oct 9, 2026, down 0.03% from the previous close of $902.19.

Share price, past year

1Y +23.49%

52-week range $730.37 – $927.59. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$901.95
Sep 30, 2026$908.50
Aug 31, 2026$914.13
Jul 31, 2026$825.90
Jun 30, 2026$818.32
May 29, 2026$848.94
Apr 30, 2026$850.50
Mar 31, 2026$837.05
Feb 27, 2026$818.07
Jan 30, 2026$857.28
Dec 31, 2025$863.78
Nov 28, 2025$782.48
Oct 31, 2025$774.16

Key statistics

Market cap
$5.78B
P/E (TTM)
—
EPS (TTM)
−$1.15
Revenue (TTM)
—
Net income (TTM)
−$6.69M
Shares outstanding
6.4M
Dividend yield
—
52-week range
$730.37 – $927.59

Matinas BioPharma Holdings's market cap is $5.78B, based on a share price of $901.95 and 6.4M shares outstanding as of Jun 30, 2026.

Financials

Matinas BioPharma Holdings reported revenue of $1.10M for fiscal 2023, down 65.62% from fiscal 2022.

Matinas BioPharma Holdings reported a net loss of $10.35M in fiscal 2025.

Annual revenue

FY14FY15FY16FY17FY18FY19FY20FY21FY22FY23
Annual revenue by fiscal year; the table below lists the values.
Matinas BioPharma Holdings annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2023ended Dec 31, 2023$1.10M−65.6%−$22.94M−2,093.3%−$5.28−$15.50M
FY2022ended Dec 31, 2022$3.19M+9,560.6%−$21.00M−658.6%−$0.10−$20.05M
FY2021ended Dec 31, 2021$33.00K−79.2%−$23.28M−70,554.6%−$0.11−$15.48M
FY2020ended Dec 31, 2020$158.33K+76.3%−$22.45M−14,177.0%−$0.12−$17.37M
FY2019ended Dec 31, 2019$89.81K−25.0%−$17.37M−19,343.4%−$0.13−$14.50M
FY2018ended Dec 31, 2018$119.75K−20.0%−$14.08M−11,760.4%−$0.15−$10.86M
FY2017ended Dec 31, 2017$149.69K—−$15.49M−10,345.9%−$0.36−$12.40M
FY2016ended Dec 31, 2016$0.00−100.0%−$7.60M—−$0.21−$6.12M
FY2015ended Dec 31, 2015$194.49K————−$7.89M
FY2014ended Dec 31, 2014$0.00—————
Matinas BioPharma Holdings quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q1 FY2023ended Mar 31, 2023$1.10M——
Q3 FY2022ended Sep 30, 2022$1.06M——
Q2 FY2022ended Jun 30, 2022$1.06M——
Q1 FY2021ended Mar 31, 2021$33.33K——
Q3 FY2020ended Sep 30, 2020$95.83K——
Q2 FY2019ended Jun 30, 2019$89.81K——
Q2 FY2018ended Jun 30, 2018$89.81K——
Q1 FY2018ended Mar 31, 2018$29.94K——

Company profile

Name
Matinas BioPharma Holdings, Inc.
Ticker
MTNB
Exchange
AMEX
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
1545 Route 206 South, Suite 302, Bedminster, NJ 07921
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001582554

Recent SEC filings

Frequently asked questions

What is Matinas BioPharma Holdings's stock price?

Matinas BioPharma Holdings (MTNB) closed at $901.95 on Oct 9, 2026, down 0.03% from the previous close of $902.19.

What is Matinas BioPharma Holdings's market cap?

Matinas BioPharma Holdings's market cap is $5.78B, based on a share price of $901.95 and 6.4M shares outstanding as of Jun 30, 2026.

How much revenue does Matinas BioPharma Holdings make?

Matinas BioPharma Holdings reported revenue of $1.10M for fiscal 2023, down 65.62% from fiscal 2022.

Does Matinas BioPharma Holdings pay a dividend?

Matinas BioPharma Holdings's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Matinas BioPharma Holdings, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures